Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670549 | 1.00 | CCR2 (0.36) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL8102807 | 0.90 | CCR2 (0.38) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL8102812 | 0.90 | CCR2 (0.38) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL5669430 | 0.90 | CCR2 (0.38) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL8095133 | 0.89 | GAA (0.38) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL8095140 | 0.89 | GAA (0.38) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL7456007 | 0.83 | CCR2 (0.41) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL7456001 | 0.83 | CCR2 (0.41) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL7453530 | 0.83 | CCR2 (0.36) | CCR2EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL7453533 | 0.83 | CCR2 (0.36) | CCR2EPHX2DPP8DPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041660-B2 | Crystalline 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-05-09 | — | — | US | disclosed |
| US-6924279-B2 | Crystalline 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040132668-A1 | Crystalline 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-08 | — | — | US | disclosed |
| US-20030232803-A1 | Crystalline 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-18 | — | — | US | disclosed |
| US-20030158174-A1 | Crystalline 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1193269-A1 | CRYSTALLINE 1-METHYLCARBAPENEM COMPOUNDS | Sankyo Company, Limited (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158174-A1 | Crystalline 1-methylcarbapenem derivatives | MGAM, CYP51A1, MRPL21 | CCR2 2625/4885EPHX2 4416/4885DPP8 2746/4885 |
| US-20030232803-A1 | Crystalline 1-methylcarbapenem derivatives | MGAM, CYP51A1, MRPL21 | CCR2 2625/4885EPHX2 4416/4885DPP8 2746/4885 |
| US-20040132668-A1 | Crystalline 1-methylcarbapenem derivatives | MGAM, CYP51A1, MRPL21 | CCR2 2625/4885EPHX2 4416/4885DPP8 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.